TY - JOUR
T1 - Quality Assurance and Good Manufacturing Practices for Processing Hematopoietic Progenitor Cells
AU - McCullough, Jeffrey
PY - 1995/12
Y1 - 1995/12
N2 - Hematopoietic progenitor cell processing is now only a part of somatic cell and gene therapy. As these new therapies become used increasingly, it is essential that the new products used to treat patients be as safe and effective as possible. Although progenitor cell processing is still an evolving activity, it is appropriate to introduce standardization and product and process control into the routine laboratory activities. Initial suggestions for quality assurance and good manufacturing practices to accomplish this are presented here. These will need to be modified as experience is gained with progenitor, somatic cell, and gene therapy.
AB - Hematopoietic progenitor cell processing is now only a part of somatic cell and gene therapy. As these new therapies become used increasingly, it is essential that the new products used to treat patients be as safe and effective as possible. Although progenitor cell processing is still an evolving activity, it is appropriate to introduce standardization and product and process control into the routine laboratory activities. Initial suggestions for quality assurance and good manufacturing practices to accomplish this are presented here. These will need to be modified as experience is gained with progenitor, somatic cell, and gene therapy.
UR - http://www.scopus.com/inward/record.url?scp=0029564216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029564216&partnerID=8YFLogxK
U2 - 10.1089/scd.1.1995.4.493
DO - 10.1089/scd.1.1995.4.493
M3 - Article
C2 - 8846009
AN - SCOPUS:0029564216
SN - 1525-8165
VL - 4
SP - 493
EP - 501
JO - Journal of Hematotherapy and Stem Cell Research
JF - Journal of Hematotherapy and Stem Cell Research
IS - 6
ER -
